WallStSmart

SAGTEC GLOBAL LIMITED Ordinary shares (SAGT)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 210% more annual revenue ($258.90M vs $83.41M). SAGT leads profitability with a 17.4% profit margin vs -15.5%. SAGT earns a higher WallStSmart Score of 70/100 (B).

SAGT

Strong Buy

70

out of 100

Grade: B

Growth: 9.3Profit: 9.0Value: 6.7Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for SAGT.

ZEPPUndervalued (+48.8%)

Margin of Safety

+48.8%

Fair Value

$46.82

Current Price

$18.43

$28.39 discount

UndervaluedFair: $46.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SAGT6 strengths · Avg: 9.0/10
P/E RatioValuation
5.5x10/10

Attractively priced relative to earnings

Return on EquityProfitability
45.0%10/10

Every $100 of equity generates 45 in profit

EPS GrowthGrowth
84.4%10/10

Earnings expanding 84.4% YoY

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.4%8/10

Strong operational efficiency at 23.4%

Revenue GrowthGrowth
25.1%8/10

Revenue surging 25.1% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

SAGT1 concerns · Avg: 3.0/10
Market CapQuality
$21.68M3/10

Smaller company, higher risk/reward

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : SAGT

The strongest argument for SAGT centers on P/E Ratio, Return on Equity, EPS Growth. Profitability is solid with margins at 17.4% and operating margin at 23.4%. Revenue growth of 25.1% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : SAGT

The primary concerns for SAGT are Market Cap.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

SAGT profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SAGT scores higher overall (70/100 vs 41/100), backed by strong 17.4% margins and 25.1% revenue growth. ZEPP offers better value entry with a 48.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

SAGTEC GLOBAL LIMITED Ordinary shares

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Sagtec Global Limited provides customizable software development services in Malaysia. The company is headquartered in Kuala Lumpur, Malaysia.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?